TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05177796
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05177796
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05995704
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to apraglutide
Study: NCT05995704
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen mixed with a liquid meal
Study: NCT05013437
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg once orally within 30 minutes before Evomela
Study: NCT06386328
Drug: CKD-378, QD, PO
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD-378, QD, PO
Study: NCT06051630
Drug: Serum saline intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative serum saline intravenous administration
Study: NCT06548815
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending single doses - 4 dose levels.
Study: NCT05252598
Drug: Inonotus Obliquus Whole Extract
Normalized name: Inonotus obliquus whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg encapsulated chaga mushroom
Study: NCT05011396
Drug: Placebo Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray delivered 20 minutes before the public speaking stressor
Study: NCT05666089
Drug: Calcium hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: intracanal medication of calcium hydroxide paste (metapaste)
Study: NCT05432544
Drug: SHR-1918 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending dose
Study: NCT04444245
Drug: Normal Saline (NS) .9% 10 mL Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 cc Sterile Normal Saline for Injection
Study: NCT05896007
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3.5 g/m\^2 ivgtt, D1 of each 28-day cycle
Study: NCT06593457
Drug: IP
Normalized name: GIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: NX-5948 oral
Study: NCT06399783
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group of patients will be treated by topical application of simvastatin cubosomal nanoparticled twice daily for 6 months, while another group will be treated by fractional CO2 laser for 6 sessions sessions each will be followed immediately by topical application of topical simvastatin.
Study: NCT06226402
Drug: Hypertonic saline 3% nebulizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive the standard pharmacotherapy + hypertonic saline 3% (5ml) nebulizer /8hr.
Study: NCT06226402
Drug: Intravenous hypertonic saline 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive the standard pharmacotherapy + hypertonic saline 3% intravenous over 24 hours to maintain plasma Na level between 145-150 mEq/L.
Study: NCT06326944
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients will receive an induction dose at 1 mcg/kg. If the analgesia was inadequate in the form of increase in heart rate and or arterial blood pressure by more than 20% of baseline values during surgery, this warrants the administration of intravenous fentanyl (0.5µg/kg).
Study: NCT06326944
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will be given paracetamol (15 mg /kg/8 hrs ).
Study: NCT06294600
Drug: Clarithromycin 500mg
Normalized name: CLARITHROMYCIN 500MG TAB
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablets of 500mg of clarithromycin
Study: NCT05153343
Drug: flonoltinib 25mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 case,The starting dose,Take the medicine once on D1,D 5-21.
Study: NCT05153343
Drug: flonoltinib 50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 case,The starting dose,Take the medicine once on D1,D 5-21.
Study: NCT05153343
Drug: flonoltinib 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 case,The starting dose,Take the medicine once on D1,D 5-21.
Study: NCT05153343
Drug: flonoltinib 150mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 case,The starting dose,Take the medicine once on D1,D 5-21.
Study: NCT05153343
Drug: flonoltinib 225mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 case,The starting dose,Take the medicine once on D1,D 5-21.
Study: NCT05153343
Drug: flonoltinib 325mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 case,The starting dose,Take the medicine once on D1,D 5-21.
Study: NCT04954365
Drug: Rescue Post-Operative Nausea and Vomiting (PONV) treatment according to the standard of care (SOC)
Normalized name: Pepto Nausea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue Post-Operative Nausea and Vomiting (PONV) treatment
Study: NCT05047523
Drug: ALXN1840
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an oral tablet.
Study: NCT05047523
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depending on the site/region, participants randomized to receive Standard of Care treatment will receive trientine, penicillamine, zinc, or a combination of these medicines, administered according to standard regimens.
Study: NCT04918121
Drug: Yutiq 0.18 MG Drug Implant
Normalized name: Yutiq 0.18 MG Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: a sustained-release steroid insert (Yutiq)
Study: NCT04397484
Drug: 2% Xylocaine with adrenaline 1:200,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: The plane where the sciatic nerve bifurcates will at first be identified by utlrasound. 22-gauge insulated nerve block needle will be inserted in the short axis (out-of-plane) of the ultrasound transducer, and advanced toward the cleavage between the common peroneal nerve and the tibial nerve, which is the easiest location for needle access into subparaneural compartment.Once the needle tip enters the subparaneural compartment 2-3 ml of normal saline will be injected (hydro-distension) to create a halo around both the common peroneal nerve and tibial nerve distally and the sciatic nerve proximally. The needle is then redirected to place its tip into the paraneural sheath of the common peroneal and tibial nerve through the same skin puncture and 15ml of study drug will be injected at each site (total 30ml).
Study: NCT05637255
Drug: SYL1801
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop in the eligible eye
Study: NCT04815603
Drug: BGE-117
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Treatment
Study: NCT05318521
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The 800mg ibuprofen sustained-release tablet is the same as the next generation of ibuprofen sustained-release tablets developed by foreign pharmaceutical companies, but does not contain a placebo that the active ingredient of ibuprofen
Study: NCT05318521
Drug: Ibuprofen modified release tablet 800 mg
Normalized name: ibuprofen Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication: ibuprofen modified sustained release tablets 800 mg Ibuprofen sustained Release Tablet 800mg is a new generation of ibuprofen developed by overseas pharmaceutical companies. It works fast and lasts for up to 12 hours. The dosing regimen was twice daily, 12 hours apart. Ibuprofen :2-\[4-(2-methylpropyl) phenyl\] propionic acid, nonselective nonsteroidal anti-inflammatory drug (NSAID).
Study: NCT05816681
Drug: DWJ1230
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daewoong Pharmaceutical
Study: NCT05816681
Drug: DWB2001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daewoong Bio
Study: NCT06003062
Drug: Narcissus Tazetta Bulb Extract and Novel Hemp Extract
Normalized name: Narcissus tazetta bulb extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nightly application of phytonutraceutical
Study: NCT06266221
Drug: Oral Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo
Study: NCT06266221
Drug: IV Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV placebo
Study: NCT06437223
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 40mg, Two tablets per day
Study: NCT04970329
Drug: Polyethylene Glycol 400 0.4%-Propylene Glycol 0.3%. and Dextran 0.1%Hypromellose 0.3%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs will be given to two group and third group will kept on placebo.
Study: NCT06615674
Drug: Forxiga® 10 mg Film-Coated Tablet, manufactured by AstraZeneca Pharmaceuticals LP, USA for AstraZeneca Pharmaceuticals Co. Ltd., China imported by PT AstraZeneca Indonesia, Indonesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first group is the Dapagliflozin group, which will get Dapagliflozin 10mg once a day every morning for 14 days. And the second group will have placebo for 14 days.
Study: NCT04791579
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill
Study: NCT06021678
Drug: EX103 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT00889096
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of placebo (1 gelatine capsules; content: 1 tablet placebo; microcrystalline cellulose, magnesium stearate, cellulose powder, lactose monohydrate) according to randomization list with 240 ml tap water.
Study: NCT05281276
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During the run-in period, the patients will take a single dose of celecoxib on Day 1. In a treatment cycle, the dosing schedule is one capsule(200 mg) daily.
Study: NCT06667453
Drug: PGN-EDODM1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by intravenous (IV) infusion
Study: NCT06349980
Drug: HLX53 (1000mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLX53 will be administered by IV infusion at a fixed dose of 1000 mg on Day 1 of each 21-day cycle.
Study: NCT06349980
Drug: HLX53 (2000mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLX53 will be administered by IV infusion at a fixed dose of 2000 mg on Day 1 of each 21-day cycle.
Study: NCT05841940
Drug: [14C]HLX208
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbon-14 labeled HLX208
Study: NCT06329050
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of Placebo tablets
Study: NCT04651634
Drug: MIT-001 plus CCRT
Normalized name: menthol 0.001 MG/MG [Lysine Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIT-001 IV-infusion plus CCRT
Study: NCT01931514
Drug: Singulair® (Montelukast Sodium) Chewable Tablets 5mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06607185
Drug: LY4066434.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT06607185
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously.
Study: NCT06607185
Drug: 5Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously.
Study: NCT06602726
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered per the protocol
Study: NCT05340504
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A and Group B will receive Placebo. Group A will receive Placebo as their first 14 day condition and Group B will receive Placebo as their second 14 day condition. Participants will take Placebo Oral Capsule for 14 days and then have a MRI exam after completing various assessments (clinical interview, questionnaires, etc).
Study: NCT06673082
Drug: Oral zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Zinc will be supplemented to the interventional group on a dose of 30 mg elemental zinc/day.
Study: NCT06527391
Drug: choline bitartrate
Normalized name: Choline Bitartrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation for 9 months with 200 mg choline bitartrate
Study: NCT06677203
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules
Study: NCT06075953
Drug: Testosterone + Anastrazole
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Investigational drug. Both pre- and post- menopausal subjects. 100mg testosterone in combination with 4mg anastrazole administered subcutaneously every 3 months for up to 3 years.
Study: NCT05491733
Drug: APX001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-load oral tablet
Study: NCT05491733
Drug: APX001A
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-load oral tablet
Study: NCT04964258
Drug: TAK-105-a Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-105-a placebo-matching solution.
Study: NCT04791943
Drug: Melatonin 10 MG
Normalized name: melatonin 10 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 melatonin 10mg capsules will be given to the treatment arm
Study: NCT04791943
Drug: Lactose pill
Normalized name: lactose Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 lactose pills will be provided to the control arm
Study: NCT06002152
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After anesthesia induction and prior to the start of surgery, the superficial cervical plexus block will be performed according to standard protocol by an experienced blinded clinician. In this arm, participants will receive 10 milliliters of saline on both sides of their neck for this block. This will be the only intervention administered for purposes of this study.
Study: NCT05409417
Drug: Experimental drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilelizumab combined with XELOX and bevacizumab or tislelizumab combined with FOLFOX and cetuximab
Study: NCT05021809
Drug: Calcium hydroxide intracanal medication application
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will be anaesthized with Articaine hydrochloride 40 mg/ml + 1/100000 Epinephrine bitartrate solution . Then the rubber dam isolation will be conducted, the access will be opened and then cleaning and shaping will be done by using Protaper Next rotary file system and irrigation by sodium hypochlorite 2.5% by side vented needle, EDTA 17%, sodium hypochlorite and the final rinse by saline where the canal will be dried by absorbent paper point. The application of calcium hydroxide intracanal medication will be done according to the manufacturer instructions then temporization by glass ionomer will be applied .
Study: NCT06612424
Drug: ANTERİOR QUADRATUS LUMBORUM BLOCK
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the Quadratus Lumborum block group, Participants will be placed in the lateral decubitus position. A convex ultrasound probe will be placed in sterile conditions along the midaxillary line, in the subcostal area above the iliac crest, to visualize the quadratus lumborum and psoas major muscles, as well as the L4 vertebral transverse process. Using an in-plane technique, a 22G, 100 mm peripheral block needle will be advanced anterior to the quadratus lumborum muscle and into the subfascial space between the quadratus lumborum and psoas major muscles. After confirming the correct location with hydrodissection, 25 mL of 0.25% bupivacaine will be injected slowly, observing the fascial displacement on ultrasound. The same procedure will be repeated on the contralateral side.
Study: NCT06612424
Drug: İNTRATECHAL MORPHİNE GROUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the intrathecal morphine group, 100 micrograms of morphine (0.1 mL) will be added to the 12 mg of intrathecally administered bupivacaine.
Study: NCT06672523
Drug: [14C]-BMS-986504
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06671002
Drug: Opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once randomized to this group the surgical team will elect to prescribe for 1 of the following treatment options to be given post procedure for post-discharge pain:~* Oxycodone 0.1 mg/kg (maximum 5 mg) by mouth every 4 to 6 hours as needed for pain, number 10 doses.~* Hydromorphone 0.04 mg/kg (maximum mg) by mouth 4 to 6 hours as needed, number 10 doses
Study: NCT06671002
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 15mg/kg up to 1000mg by mouth every 6 hours around the clock for the first 2 days after discharge from surgery then as needed thereafter (40 doses)
Study: NCT06671002
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 10mg/kg (maximum 600 mg) by mouth every 6 hours around the clock for 2 days after discharge from surgery then as needed thereafter (40 doses)
Study: NCT06672900
Drug: ALG-000184
Normalized name: DRESSING,BIATAIN ALG 2IN X 2IN C#3705
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study Investigational Product
Study: NCT06432127
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral Greater occipital nerve block at C2 level under ultrasound guide with needle in plane technique during ultrasound using normal saline 3 mL
Study: NCT06598397
Drug: Combination NRT
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: If they smoke 10 or more cigarettes per day (CPD), participants will receive 2 weeks of 21 mg patches, 2 weeks of 14 mg patches and 2 weeks of 7 mg patches; if they smoke less than 10 CPD, participants will receive 4 weeks of 14 mg patches and 2 weeks of 7 mg patches. Participants will receive either 2 or 4 mg of nicotine lozenges for a total of up to 20 lozenges per day.
Study: NCT06678542
Drug: GP681 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP681 tablet, 20 mg, single oral dose in each Group.
Study: NCT06678542
Drug: GP681 Powder for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP681 Powder for Oral Suspension, 20 mg, single oral dose in each Group.
Study: NCT06677710
Drug: IDP-023
Approvals — FDA: no, EMA: no, PMDA: no
Description: NK cell therapy
Study: NCT06677710
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lymphodepleting chemotherapy
Study: NCT06677918
Drug: EP395
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule for oral use
Study: NCT06677918
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule for oral use
Study: NCT00246168
Drug: tramadol hydrochloride + acetaminophen
Normalized name: acetaminophen / tramadol hydrochloride Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00365755
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05232734
Drug: Caffeine Citrate 20 MG/ML Oral Solution
Normalized name: Caffeine citrate 20 mg/mL oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine syrup will be prepared by pharmacy laboratory and kept refrigerated (2-8C), to be used within 1 month from the date of preparation by pharmacy laboratory.
Study: NCT06601192
Drug: zelicapavir (therapeutic dose)
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive zelicapavir (TD) once per treatment period.
Study: NCT06601192
Drug: zelicapavir (supratherapeutic dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive zelicapavir (SD) once per treatment period.
Study: NCT06601192
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive zelicapavir matching placebo once per treatment period.
Study: NCT06656416
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet BID
Study: NCT06656962
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide, intravenous injection, once every 2 to 3 weeks, 0.75 g/m² each time, the maximum cumulative dose of 8g
Study: NCT06656091
Drug: simmitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: simmitinib 6mg,QD ,3 weeks on 1 week off
Study: NCT05439616
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules or Oral Solution
Study: NCT05516914
Drug: LBL-007 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dose - MTD; Q3W; intravenous infusion
Study: NCT04892563
Drug: IV Analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV analgesia, typically Morphine/Opioid medications
Study: NCT06151925
Drug: Vaginal prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal prostaglandin for ripening
Study: NCT05041166
Drug: Hyperpolarized [13C] Pyruvate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will be injected at a dosage of 0.43 ± 0.05 mL/kg body weight
Study: NCT05135364
Drug: TKI
Normalized name: Catkin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib or Regorafenib
Study: NCT05250856
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, (0.9% Sodium Chloride for IV infusion)
Study: NCT06462716
Drug: BY101298 Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: An oral DNA-PK Inhibitor
Study: NCT05181605
Drug: Folfirinox and Stereotactic Body Radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant treatment is composed of folfirinox plus stereotactic body radiotherapy
Study: NCT01606982
Drug: MDV3100
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT05169671
Drug: ATH-1020
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATH-1020 in oral capsule form
Study: NCT05169671
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in oral capsule form
Study: NCT05418712
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to VX-150 for oral administration.
Study: NCT06001606
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vaccination
Study: NCT06231043
Drug: Diclofenac/Tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm Drug1 :Diclofenac 75 mg (3 ml) IM injection by doctor, then followed by normal saline 20 ml IV injection (equal to Tramadol diluted) by nurse.~Arm Drug2 :Normal saline 3 ml IM injection by doctor (equal to Diclofenac 75 mg), then followed by Tramadol 50 mg (1 ml) dilute with normal saline 19 ml (total 20 ml )IV injection by nurse.
Study: NCT05005884
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription of oral phenolics 250 mg two times daily
Study: NCT04095858
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion, 100 ml at Day -1, Day 14, and Day 28.